Nurix Therapeutics Inc.

10/19/2024 | Press release | Distributed by Public on 10/19/2024 07:59

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.